What does the FY13 NIH Congressional Justification Say?

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

Now that I have recovered (more or less) from some particularly hellish Cycle I submissions, I can turn my attention to other matters until the Cycle II crunch begins. February is the time that the Appropriation process begins at NIH. On February 13, the Administration released their Congressional Justification for FY13, which runs from October 1, 2012 – September 30, 2013. Click here for the full report.

President Obama is requesting $30.86 billion for FY13, essentially freezing the budget at FY12 levels. There is a great deal of language in the report concerning the economy—specifically, NIH’s efforts to reduce health care costs and disease burden on society, as well as the economic growth associated with the research enterprise supported by NIH. From the cover letter:

“With continued support, NIH investigators will help to revolutionize patient care, reduce the growth of health care costs, and generate significant national economic growth… NIH must continue to seek innovative solutions to ensure rapid advances in science even in these uncertain economic times. Strategic investments will support research with the highest potential for improving public health and to preserve the scientific workforce… Investment in the future of public health has never been more important. In addition to the health benefits to all Americans in the future, such investment can play a key role in reinvigorating the economy now. Numerous economic analyses have illustrated the role that NIH research plays in creating jobs and spurring economic growth. In the face of growing global competition investment in biomedical and behavioral research and the scientific workforce will propel scientific discovery for the benefit of human health and the U.S. economy, both now and in the future.”

A call-out box early in the report states:

Every dollar of NIH funding generates about $2.21 in economic output.” (In Your Own Backyard, Families USA, June 2008.) 

AND

In fiscal year 2010, NIH extramural research funding generated $68.035 billion in new economic activity nationwide and supported more than 487,900 jobs.” (An Economic Engine, United for Medical Research, Spring 2011.)

In a budget briefing on Feb 15, NIH Director Francis Collins stated that despite the budget freeze, the President’s budget proposal would allow a 7% increase in new and competing RPGs in FY13. He stated that this increase would be made possible because there was an increased turnover in grants (i.e., decrease in the duration of grants because “science is moving more quickly” than it has in the past), together with a 1% reduction to noncompeting grants.

Other items of interest in the report:

  • Funds are sought from the Public Health Prevention Fund (part of the Affordable Care Act) to make a significant increase in Alzheimer’s research.
  • The ratio of funding between basic and applied research (54% basic, 46% applied) remains constant -as has been the case for several years.
  • The National Center for Advancing Translational Sciences (NCATS) would receive an 11% increase to $639 million, which includes significant funding ($50 million) for the Cures Acceleration Network.
  • The overall Health and Human Services budget request is 8.5% lower than last year.
  • The request for the National Science Foundation is up 5% to $7.373 billion.
  • The request for the Agency for Healthcare Research and Quality (AHRQ) is up by roughly 1% to $408.8 million. However, the proposal cuts investigator-initiated research grants by more than 31%, and comparative effectiveness research grants by 41%.

The Administration’s Congressional Justification is drawing criticism from the research community, who are quick to point out that when adjust for inflation, NIH funding has been in decline since 2003. Yet up until now, NIH has been spared the devastating budget cuts seen in many agencies in the past few years. It is likely that their luck has run out, given that virtually all discretionary spending, and in particular all aspects of the Affordable Care Act, risk being slashed dramatically when the budget request reaches the Hill.

Click here for more coverage provided by the American Association for Dental Research.

Dr. Meg Bouvier

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015. She's recently worked with more than 40% of the nation's highest-performing hospitals*, four of the top 10 cancer hospitals, three of the top five medical schools for research, and 14 NCI-designated cancer centers. Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*Our clients include 9 of the top 22 hospitals as recognized by the 2023/24 US News & World Report honor roll

Categories:
Related posts

You May Also Be Interested In

Bouvier Grant Group logo white
We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

NIH October 2023 Newsletter cover